Key Longitudinal Associations With Risk and Glioblastoma Outcomes

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The goal of this observational study is to find out what factors affect the health and risks in adults with glioblastoma (GBM), a grade 4 brain cancer. The main questions it aims to answer are: * How do genetic and immune system factors impact survival and quality of life in GBM patients? * What occupational and medical history factors are linked to the risk of getting GBM? Participants will: * Fill out an online survey about their medical history and lifestyle. Participants will have the chance to give a blood sample (from the outer arm) for genetic and immune system testing. Blood samples will be given using a home collection kit provided by the study team.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• At least 18 years old

• Pathologically-confirmed diagnosis of glioblastoma multiforme (GBM) or grade 4 brain tumor

• Participant is accessible for follow-up (has a working email address)

• Participant is willing and able to comply with the study requirements

Locations
United States
North Carolina
Duke University
RECRUITING
Durham
Contact Information
Primary
Courtney E Wimberly, MSc
GBMsurvey@duke.edu
919-681-9609
Time Frame
Start Date: 2024-12-10
Estimated Completion Date: 2029-12-10
Participants
Target number of participants: 200
Treatments
Adults with Glioblastoma
This group consists of adults diagnosed with glioblastoma, a type of aggressive brain tumor. Participants are observed to identify factors influencing their outcomes, including genetic, immunologic, and personal medical history factors. The study aims to explore how these factors impact survival rates and quality of life in this patient population. There are no specific interventions. Instead, the focus is on analyzing survey data and biological samples to understand risk factors and disease progression.
Sponsors
Collaborators: StacheStrong, Glioblastoma Research Organization
Leads: Duke University

This content was sourced from clinicaltrials.gov